innerbuddies gut microbiome testing

Gut Microbiome & MASH/NASH: How Intestinal Bacteria Drive NAFLD Progression

MASH/NASH (steatohepatitis) and NAFLD progression are increasingly understood as a “gut–liver axis” problem—not just a liver issue. As intestinal ecology shifts, the gut microbiome can change the balance of fermentation products, bile acid signaling, and immune activation that ultimately influences hepatic fat accumulation, inflammation, and fibrosis risk.

In a healthier state, the intestinal barrier limits the passage of microbial components. In metabolic dysfunction–associated steatotic liver disease, dysbiosis can weaken this barrier and increase gut permeability, allowing endotoxins like lipopolysaccharide (LPS) and other bacterial metabolites to reach the liver. There, they activate inflammatory pathways (including toll-like receptor signaling) that amplify cytokine production, promote insulin resistance, and help drive hepatocyte injury.

At the same time, gut bacteria reshape key metabolic pathways tied to NASH biology—altering short-chain fatty acid profiles, transforming bile acids into more/less signaling-active forms, and generating metabolites that affect mitochondrial stress and oxidative balance. Recent research suggests that targeting dysbiosis, restoring barrier integrity, and modulating microbiome–bile acid–immune networks may offer new prevention strategies and more precise therapeutic directions for MASH/NASH.

Order Your Gut Microbiome Test for MASH/NASH Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

MASH / NASH (steatohepatitis)

MASH/NASH is a progressive form of metabolic-dysfunction–associated fatty liver disease where excess liver fat is paired with inflammation and hepatocyte injury. A central driver is the gut–liver axis: dysbiosis and increased intestinal permeability allow bacterial products like lipopolysaccharide (LPS) to reach the liver, triggering innate immune signaling and inflammatory cytokines that worsen liver injury and fuel progression from simple steatosis to steatohepatitis and fibrosis.

In this condition, the gut microbiome often shifts away from barrier-supporting, beneficial taxa toward endotoxin-producing and pro-inflammatory microbes, with altered bile acid metabolism. Loss of short-chain fatty acid producers weakens barrier integrity and heightens inflammatory signaling, while changes in FXR/TGR5 signaling link gut microbes to impaired glucose and lipid regulation. Diet and microbiome-targeted therapies (prebiotics, probiotics, synbiotics, and bile-acid–modulating approaches) are being explored to restore balance and slow fibrosis.

Microbiome testing can reveal dysbiosis patterns, SCFA balance, and bile acid signaling tendencies that influence risk and treatment response. Serial profiling may help tailor nutrition and gut-targeted interventions, monitor improvements in barrier function and inflammatory signals, and potentially reduce pro-fibrotic risk. The article also notes how InnerBuddies provides personalized gut–liver insights to guide risk assessment and optimize therapy.

  • Loss of butyrate-producing gut bacteria (Faecalibacterium prausnitzii, Roseburia spp., Coprococcus spp., Butyrivibrio spp., Anaerostipes spp., Subdoligranulum spp.) reduces protective SCFA signaling, weakens gut barrier, and increases LPS-driven liver inflammation in MASH/NASH.
  • Loss of barrier-supporting taxa such as Akkermansia muciniphila and Bifidobacterium spp. exacerbates intestinal permeability, enabling gut-derived toxins to reach the liver and fuel steatohepatitis.
  • Expansion of pro-inflammatory and endotoxin-producing taxa (Enterococcus spp., Escherichia coli, Streptococcus spp., Ruminococcus gnavus group, Bacteroides fragilis group, Enterobacteriaceae, Klebsiella spp., Bilophila wadsworthia) drives Toll-like receptor signaling and cytokine release that promote fibrosis risk.
  • Dysbiosis-driven remodeling of bile acid metabolism alters FXR/TGR5 signaling, worsening glucose/lipid homeostasis and inflammatory tone in the liver.
Order Your Gut Microbiome Test for MASH/NASH Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

MASLD / NAFLD spectrum

MASH/NASH (metabolic dysfunction–associated steatohepatitis and its earlier name, nonalcoholic steatohepatitis) is a progressive form of NAFLD in which excess liver fat is accompanied by inflammation and hepatocyte injury. While fatty liver alone can be relatively stable for years, the “steatohepatitis” component increases the risk of fibrosis, cirrhosis, and hepatocellular carcinoma. A key driver of this progression is a vicious cycle linking metabolic dysfunction (especially insulin resistance), liver immune activation, oxidative stress, and the signaling of microbial byproducts that reach the gut–liver axis.

The gut microbiome is central to that axis. In many people with MASH/NASH, the microbial community shifts toward configurations that promote intestinal permeability (“leaky gut”), higher production of pro-inflammatory microbial metabolites, and altered bile acid metabolism. These changes can raise exposure of the liver to bacterial products such as lipopolysaccharide (LPS) and microbial fermentation byproducts, which together activate innate immune pathways (e.g., Toll-like receptor signaling) and amplify inflammatory cytokine release. The microbiome also influences energy harvest and fat storage through metabolites like short-chain fatty acids (in some contexts protective, but often dysregulated), and it modulates host lipid metabolism—affecting hepatic fat accumulation and the trajectory from simple steatosis toward steatohepatitis.

Beyond inflammation, gut-derived pathways can worsen insulin resistance and fibrosis risk. Microbiome-driven bile acid alterations can change signaling through receptors involved in glucose and lipid homeostasis (such as FXR and TGR5), while dysbiosis may increase generation of toxic or inflammatory compounds (including certain endotoxins) and reduce beneficial metabolites that support gut barrier integrity. Emerging research suggests that targeted interventions—such as diets that favor a healthier microbial ecosystem, prebiotics/probiotics, synbiotics, and microbiome- or bile-acid–modulating therapies—may help reduce liver inflammation and slow fibrosis progression. Overall, understanding which bacteria and metabolic pathways dominate in MASH/NASH can guide more precise prevention strategies and next-generation targeted treatments.

  • Fatigue and low energy
  • Right upper abdominal discomfort or pain (heaviness/fullness)
  • Unexplained weight gain or difficulty losing weight
  • Insulin resistance signs (e.g., increased blood sugar, cravings, difficulty with metabolism)
  • Bloating, gas, and changes in bowel habits
  • Elevated liver enzymes on blood tests (ALT/AST) without clear cause
  • Jaundice (yellowing of skin/eyes) in more advanced disease
  • Swelling in the abdomen or legs (ascites/edema) in advanced stages
Order Your Gut Microbiome Test for MASH/NASH Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

MASH / NASH (steatohepatitis)

It’s relevant for people with metabolic risk factors who are concerned about progression from fatty liver to MASH/NASH, especially if they have insulin resistance, unexplained weight gain, difficulty losing weight, elevated blood sugar, or persistent fatigue/low energy. It also fits individuals whose blood tests show elevated liver enzymes (ALT/AST) without another clear cause and who want to understand how metabolic dysfunction, gut inflammation, and microbiome-driven pathways may be contributing to liver injury.

It’s especially relevant for those who notice gut-related changes alongside liver concerns—such as bloating, gas, and bowel habit changes—because dysbiosis and increased intestinal permeability (“leaky gut”) can promote liver exposure to microbial products (like LPS) that amplify inflammation. If you have right upper abdominal discomfort or a heaviness/fullness sensation, these gut–liver links may help explain why liver symptoms can track with digestive or systemic inflammatory patterns.

It can also be relevant for people already diagnosed with MASH/NASH or those at higher risk for fibrosis, including individuals with worsening metabolic control despite lifestyle efforts. If you’re experiencing signs consistent with more advanced disease (e.g., jaundice, or abdominal/leg swelling from ascites/edema), this topic is important for understanding why gut microbiome and bile acid signaling may influence disease trajectory and why diet-based microbiome therapies (prebiotics/probiotics/synbiotics), and bile-acid–modulating approaches, may be considered as part of a broader treatment plan discussed with your clinician.

MASH/NASH is a common cause of chronic liver disease worldwide, largely because it tracks closely with metabolic risk factors such as obesity and insulin resistance. In adults, NAFLD affects roughly 25–30% of the general population, and about 10–12% of adults overall have NASH/MASH. Prevalence is higher in people with type 2 diabetes (approximately 40–70% have NAFLD, with NASH/MASH present in an estimated ~25–45%), and it is also elevated in those with obesity (often around 30–60% have NAFLD, with NASH/MASH in roughly 15–30%).

Despite being common, many people have few or nonspecific symptoms early on—such as fatigue, bloating/gas, right upper abdominal discomfort, and unexplained weight gain—so the condition frequently goes unrecognized until blood tests show elevated ALT/AST or until fibrosis progresses. This “silent” nature contributes to underdiagnosis in routine care, particularly in individuals without obvious liver-related complaints. In practice, clinicians often encounter MASH/NASH through metabolic markers (insulin resistance, dysglycemia) and incidental or persistent liver enzyme elevation, even when jaundice, ascites, or leg/abdominal swelling only occur in more advanced stages.

Overall, the burden of MASH/NASH is substantial and appears to be increasing in parallel with rising obesity and type 2 diabetes rates. While only a subset of people with fatty liver will develop progressive steatohepatitis and fibrosis, population-level risk remains high: among those with NAFLD, roughly 20–40% have NASH/MASH, and a meaningful fraction may advance to advanced fibrosis or cirrhosis over time. Because the gut–liver axis and microbiome-related pathways (e.g., intestinal permeability and inflammatory microbial metabolites) are implicated in progression, symptoms that overlap with dysbiosis or metabolic dysfunction—such as bloating/altered bowel habits and insulin resistance—often cluster in affected populations, further masking the condition as it develops.

Order Your Gut Microbiome Test for MASH/NASH Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome & MASH/NASH: How Intestinal Bacteria Influence NAFLD Progression

MASH/NASH is a progressive form of NAFLD where excess liver fat is accompanied by inflammation and hepatocyte injury. A major driver of this progression is the gut–liver axis: in many people with MASH/NASH, the gut microbiome shifts toward a dysbiotic pattern that can increase intestinal permeability (“leaky gut”). When the gut barrier is compromised, bacterial byproducts such as lipopolysaccharide (LPS) and other microbial metabolites can more easily reach the liver through portal circulation, triggering innate immune signaling (including Toll-like receptor pathways) and amplifying inflammatory cytokines that worsen liver injury.

This dysbiosis also alters metabolic signaling that contributes to insulin resistance and hepatic fat accumulation—key features behind steatohepatitis. Microbiome-driven changes in fermentation products and short-chain fatty acids (which can be protective when balanced) may become dysregulated, influencing energy harvest, inflammation tone, and lipid storage. In parallel, altered bile acid metabolism (shaped by gut microbes) can shift downstream signaling through receptors such as FXR and TGR5, affecting glucose and lipid homeostasis. These pathways help explain why symptoms like fatigue, weight gain, bloating/gas, and insulin-resistance–type signs often cluster with abnormal liver enzymes in MASH/NASH.

As liver inflammation accelerates, gut-derived signals may further increase fibrosis risk by sustaining oxidative stress, immune activation, and pro-fibrotic signaling. Reduced production of gut-barrier–supporting metabolites and increased generation of inflammatory compounds can maintain the cycle of metabolic dysfunction and liver injury, which may eventually manifest as more advanced findings such as jaundice or fluid retention in severe disease. Emerging strategies—such as diets that promote a healthier microbial ecosystem, prebiotics/probiotics/synbiotics, and therapies that modulate bile acids or the microbiome—aim to restore barrier integrity, rebalance microbial metabolites, and calm gut-to-liver inflammatory signaling to help slow progression.

Order Your Gut Microbiome Test for MASH/NASH Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Gut Microbiome and MASH / NASH (steatohepatitis)

  • Gut barrier dysfunction and increased intestinal permeability (“leaky gut”)—dysbiosis reduces tight-junction integrity, allowing bacterial products (e.g., LPS) to cross into portal circulation and reach the liver.
  • Innate immune activation in the liver—gut-derived LPS and other microbial molecules trigger Toll-like receptor (TLR) pathways and Kupffer cell/NLRP3 inflammasome signaling, amplifying pro-inflammatory cytokines that drive hepatocyte injury and steatohepatitis.
  • Microbiome-driven worsening of insulin resistance and hepatic fat accumulation—altered microbial metabolites and signaling affect host glucose/lipid metabolism, promoting insulin resistance that increases de novo lipogenesis and triglyceride storage in the liver.
  • Dysregulated short-chain fatty acids (SCFAs) and fermentation products—loss of beneficial SCFA-producing taxa (e.g., butyrate producers) reduces barrier-supportive and anti-inflammatory signaling, while other metabolite shifts can increase inflammatory tone.
  • Altered bile acid metabolism and FXR/TGR5 signaling—microbial changes reshape the bile acid pool, shifting receptor signaling (FXR, TGR5) that regulates glucose homeostasis, lipid metabolism, and inflammation; this can favor steatosis and injury.
  • Pro-oxidant and pro-fibrotic metabolite generation—microbial metabolites can increase oxidative stress and sustain immune activation, promoting hepatic stellate cell activation and accelerating fibrosis progression in advanced disease.
  • Reduced microbial “detox” capacity and altered endotoxin-to-inflammation balance—imbalanced microbial communities decrease degradation/inactivation of harmful compounds while increasing exposure to inflammatory microbial products, sustaining liver inflammation over time.

MASH/NASH is not only a problem of excess liver fat—it’s a progressive inflammatory liver disease in which the gut–liver axis helps drive the transition from simple steatosis to steatohepatitis. In many people, the gut microbiome shifts into a dysbiotic pattern that weakens the intestinal barrier. When tight-junction integrity declines, intestinal permeability increases, allowing bacterial products and microbial metabolites to cross the gut lining and reach the liver via portal blood. Among the key drivers is endotoxin (for example, LPS), which can prime inflammatory signaling and set the stage for ongoing hepatocyte injury.

Once these gut-derived signals reach the liver, they amplify innate immune activation. LPS and other microbial molecules can stimulate Toll-like receptor (TLR) pathways on liver immune cells (including Kupffer cells), increasing pro-inflammatory cytokine release. This inflammatory tone can further engage inflammasome signaling (such as NLRP3), which promotes oxidative stress and deepens tissue injury—key features of steatohepatitis. At the same time, dysbiosis can worsen metabolic dysfunction: microbial metabolites and signaling changes contribute to insulin resistance, which boosts hepatic de novo lipogenesis and triglyceride storage, reinforcing the cycle of fat accumulation and inflammation.

Microbiome-driven metabolic remodeling also affects protective signaling systems, including short-chain fatty acid (SCFA) pathways and bile acid signaling. Loss of beneficial SCFA-producing bacteria (e.g., butyrate producers) can reduce barrier-supportive, anti-inflammatory effects, while other fermentation byproducts may tilt the overall balance toward a more inflammatory environment. In parallel, gut microbes reshape the bile acid pool, altering downstream receptor activity through FXR and TGR5—pathways that regulate glucose and lipid homeostasis as well as inflammatory signaling. Over time, these combined effects can increase oxidative stress and promote pro-fibrotic activation of hepatic stellate cells, increasing fibrosis risk and helping explain why gut-linked dysregulation may track with disease progression in MASH/NASH.

Order Your Gut Microbiome Test for MASH/NASH Get Your Gut Microbiome Test Subscription
innerbuddies gut microbiome testing

Microbial patterns summary

In MASH/NASH, the gut microbiome often shifts toward a dysbiotic composition characterized by loss of beneficial, barrier-supporting taxa (including SCFA producers such as butyrate-generating bacteria) and an enrichment of microbes associated with endotoxin generation and pro-inflammatory metabolite profiles. This imbalance can reduce tight-junction integrity and promote intestinal permeability, increasing the likelihood that bacterial components and fermentation byproducts reach the liver via portal circulation. The overall pattern is less about a single organism and more about a coordinated ecosystem shift that tilts the gut environment toward inflammatory tone and metabolic dysregulation.

A common feature of this dysbiosis is altered microbial metabolism, including changes in short-chain fatty acid (SCFA) production and downstream signaling. When butyrate and other protective SCFAs are reduced, the intestinal barrier is less well supported and immune signaling can become more reactive. Meanwhile, dysregulated fermentation can increase exposure to inflammatory or pro-oxidative compounds, reinforcing a gut-to-liver axis in which microbial byproducts—particularly lipopolysaccharide (LPS)—more readily trigger innate immune pathways. This frequently aligns with findings of heightened inflammatory signaling that can contribute to hepatocyte injury and sustain steatohepatitis rather than remaining simple steatosis.

Gut-driven remodeling of bile acid metabolism is another frequently observed microbial pattern in MASH/NASH. Because gut microbes convert and recycle bile acids, dysbiosis can change the balance of bile acid species and alter activation of receptors such as FXR and TGR5, which normally help regulate glucose and lipid homeostasis and modulate inflammation. In this context, bile acid pool changes can further amplify insulin resistance and hepatic fat accumulation while also influencing inflammatory cascades that promote oxidative stress. Over time, these interconnected microbial and metabolic shifts may contribute to progressive disease, including increased pro-fibrotic signaling and higher fibrosis risk.


Low beneficial taxa

  • Faecalibacterium prausnitzii
  • Roseburia spp.
  • Coprococcus spp.
  • Butyrivibrio spp.
  • Anaerostipes spp.
  • Subdoligranulum spp.
  • Bifidobacterium spp.
  • Akkermansia muciniphila


Elevated / overrepresented taxa

  • Enterococcus spp.
  • Escherichia coli (E. coli)
  • Streptococcus spp.
  • Ruminococcus gnavus group
  • Bacteroides fragilis (B. fragilis group)
  • Proteobacteria (class/order-level; e.g., Enterobacteriaceae, Desulfovibrionaceae)
  • Klebsiella spp.
  • Bilophila wadsworthia


Functional pathways involved

  • Short-chain fatty acid (SCFA) biosynthesis and butyrate fermentation (loss of butyrate producers; reduced barrier-supportive signaling)
  • Bacterial endotoxin (LPS) generation and lipopolysaccharide biosynthesis (increased portal inflammatory tone and innate immune activation)
  • Microbial amino acid fermentation to pro-inflammatory and potentially pro-oxidative metabolites (e.g., branched-chain amino acid–linked pathways; ammonia/phenolic outputs)
  • Bile acid secondary modification and bile acid metabolism (microbial conversion/recycling altering FXR/TGR5 signaling and hepatic lipid/inflammation control)
  • Intestinal barrier integrity disruption via microbial proteases and mucin-degrading metabolism (weakened tight junction support; increased permeability)
  • Tryptophan metabolism through inflammatory indole derivatives and aryl hydrocarbon receptor (AhR) signaling (immune modulation toward steatohepatitis-promoting tone)


Diversity note

In MASH/NASH, the gut ecosystem often shows reduced overall diversity and a shift away from beneficial, barrier-supporting microbial communities. Taxa that normally help maintain gut-lining tight junctions—particularly microbes involved in producing protective short-chain fatty acids (SCFAs) like butyrate—tend to be depleted. At the same time, there is commonly enrichment of organisms associated with endotoxin generation and pro-inflammatory metabolic outputs, creating a gut environment that is more prone to intestinal permeability.

These diversity changes matter because a less balanced microbiome alters how the gut handles fermentation and inflammatory byproducts. With lower SCFA production and dysregulated fermentation, the intestinal barrier can become less resilient, which increases the likelihood that bacterial components such as lipopolysaccharide (LPS) and other microbial metabolites reach the liver via portal circulation. This promotes innate immune activation and sustains the inflammation–injury cycle that characterizes steatohepatitis, rather than leaving liver disease limited to fat accumulation.

Microbiome diversity shifts in MASH/NASH are also linked to remodeled bile acid metabolism. When microbial composition and metabolic capacity change, the bile acid pool can become imbalanced, affecting signaling through receptors such as FXR and TGR5 that influence glucose and lipid homeostasis and modulate inflammatory tone. Overall, the reduced diversity and functional “rewiring” of the gut community help explain why metabolic dysfunction and inflammatory signaling often travel together in progressive MASH/NASH.


Order Your Gut Microbiome Test for MASH/NASH Get Your Gut Microbiome Test Subscription

Why generic solutions fail

  • Issue with generic solutions

    Generic solutions often fail in MASH/NASH because the condition is not driven by a single “bad microbe” or one pathway—it’s driven by a coordinated gut–liver ecosystem shift that affects intestinal barrier integrity, immune activation, metabolic signaling, and bile-acid signaling all at once. Many broadly marketed probiotic or prebiotic approaches assume that increasing “good bacteria” alone will be sufficient, but in dysbiotic MASH/NASH, the limiting factors are frequently strain-specific functions (e.g., robust SCFA/butyrate production, tight-junction support, reduced endotoxin-associated metabolite profiles) and the host’s baseline metabolic state (insulin resistance, altered bile acids, and ongoing inflammation). Without targeting those functions, interventions may not meaningfully reduce permeability or the gut-to-liver influx of microbial products such as LPS.

    They can also fail because the gut microbiome’s contribution to steatohepatitis depends heavily on context—particularly diet pattern, bile acid pool composition, and the receptor-driven downstream pathways (FXR/TGR5) that mediate glucose and lipid homeostasis. Microbes reshape bile acids, and bile acids then feed back on the microbiome and immune tone; a generic strategy may change stool consistency or symptom burden without shifting the bile-acid signaling axis that influences hepatic fat accumulation and inflammatory cascades. In addition, protective SCFAs may be reduced in MASH/NASH, and simply “adding fibers” without the right fermentability profile and dosing can be insufficient, or may even worsen bloating in sensitive individuals, limiting adherence.

    Finally, many generic regimens overlook that worsening fibrosis risk in MASH/NASH is often sustained by chronic innate immune activation and oxidative stress linked to persistent gut-derived triggers. If an approach does not meaningfully lower endotoxin/pro-inflammatory metabolite exposure, rebalance microbial metabolic output (including SCFAs and other fermentation-derived signals), and improve barrier function over time, the inflammation–injury cycle continues even if weight or liver enzymes improve transiently. In practice, MASH/NASH requires therapies aligned to the gut–liver axis drivers—strain/function specificity, bile-acid/microbial metabolism awareness, and sustained barrier-supporting effects—otherwise the treatment may not address the underlying mechanisms that make the disease progressive.

  • Common mistakes

    • Assuming MASH/NASH is caused by a single “bad microbe,” rather than a coordinated dysbiotic ecosystem that drives barrier dysfunction, immune activation, and metabolic/bile-acid signaling.
    • Using generic probiotics/prebiotics that don’t reliably deliver the specific strain functions needed (e.g., robust butyrate/SCFA production, competitive exclusion of endotoxin-associated profiles, or direct tight-junction support).
    • Targeting stool regularity or “adding fiber” without matching fermentability, dose, and tolerability to the patient’s dysbiosis—leading to inadequate SCFA benefits or poor adherence (e.g., bloating/worsened symptoms).
    • Overlooking the gut–bile acid axis (FXR/TGR5 signaling): interventions that change microbiome composition without meaningfully rebalancing bile acid species and downstream metabolic/inflammatory pathways.
    • Failing to reduce gut-derived inflammatory triggers such as endotoxin/LPS exposure by improving intestinal permeability over time—so the gut–liver inflammation–injury cycle persists even if labs temporarily improve.
    • Ignoring host context (baseline insulin resistance, metabolic state, ongoing inflammation, medication/diet effects), which strongly determines whether microbiome changes translate into hepatoprotective effects.
    • Not considering that “good bacteria” additions may be insufficient when protective SCFA-producing taxa are depleted and dietary substrates are mismatched to restore SCFA signaling.
    • Underestimating fibrosis risk: focusing only on short-term steatosis or enzyme improvements rather than sustained reduction of innate immune activation, oxidative stress, and pro-fibrotic signaling linked to gut triggers.

What to do

  • General support strategies

    For MASH/NASH, general support focuses on reducing the drivers of gut–liver inflammation while improving metabolic health. Since dysbiosis and impaired intestinal barrier function can allow bacterial byproducts (such as LPS) and microbial metabolites to reach the liver via portal circulation, strategies that restore barrier integrity and rebalance the microbiome may help calm innate immune activation and downstream cytokine signaling. Clinically, this often overlaps with lifestyle patterns that lower hepatic fat, including dietary approaches that reduce added sugars and refined carbohydrates, support healthy weight management, and promote consistent fiber intake to nourish beneficial microbial taxa.

    A gut-supportive diet typically emphasizes diverse, high-fiber plant foods (vegetables, legumes, whole grains, nuts, and seeds) to increase production of protective short-chain fatty acids like butyrate. These metabolites help strengthen the gut barrier, modulate inflammatory tone, and improve insulin sensitivity—key factors in steatohepatitis progression. For some people, targeted prebiotic, probiotic, or synbiotic interventions may further support a healthier microbial ecosystem; probiotics can help reduce dysbiosis-related signaling, while prebiotics provide fermentable substrates for beneficial bacteria. Because bile acid signaling also plays a major role in MASH/NASH, fiber and microbiome-modulating foods can indirectly influence bile acid composition and downstream receptors (e.g., FXR/TGR5), which are involved in glucose and lipid homeostasis.

    Overall, support strategies aim to break the cycle linking metabolic dysfunction, gut barrier impairment, and liver injury. This includes maintaining regular physical activity, prioritizing sleep and stress management (which can influence metabolic and microbial rhythms), and using a sustained nutrition plan rather than short-term changes. In practice, clinicians may tailor gut-targeted options to individual tolerance and lab/clinical status, especially when symptoms such as bloating or abnormal liver enzymes are present, with the goal of improving gut-liver communication and slowing progression toward fibrosis.

  • Lifestyle recommendations

    • Adopt a Mediterranean-style diet (emphasize vegetables, legumes, whole grains, nuts, olive oil, and lean proteins; limit refined carbohydrates, sugary beverages/foods, and ultra-processed foods).
    • Aim for gradual, sustained weight loss if overweight (target ~5–10% of baseline weight over time, as this can improve liver fat and inflammation).
    • Engage in regular physical activity (mix of aerobic exercise and resistance training most weeks; at least 150 minutes/week of moderate aerobic activity plus strength work).
    • Limit alcohol intake or avoid alcohol entirely (to reduce additional liver injury and inflammation).
    • Reduce added sugars and fructose sources (especially drinks and sweets) to improve insulin resistance and hepatic steatosis.
    • Support gut barrier health by prioritizing dietary fiber (≥25–38 g/day from whole foods; consider prebiotic-rich foods like onions, garlic, leeks, asparagus, oats, and bananas—if tolerated).
    • Maintain healthy sleep and manage stress (consistent sleep schedule and stress-reduction practices such as mindfulness/yoga) to help insulin sensitivity and metabolic regulation.
    • Review medications and metabolic risk factors with a clinician (optimize treatment for diabetes, dyslipidemia, and hypertension; avoid unnecessary hepatotoxic drugs/supplements).

  • Nutrition recommendations

    • Adopt a Mediterranean-style eating pattern (vegetables, legumes, whole grains, nuts, olive oil, fish) and limit refined carbs and added sugars to reduce hepatic fat accumulation and downstream inflammatory signaling.
    • Increase fiber to a consistent daily target (≈25–38 g/day) using legumes, whole grains, fruits/berries, and non-starchy vegetables to support a healthier microbiome and gut barrier function.
    • Prioritize prebiotic fibers and microbiome-supportive foods (e.g., inulin/FOS sources like chicory, garlic/onion, leeks, asparagus; plus oats and cooked/cooled potatoes/rice for resistant starch) to promote beneficial short-chain fatty acid production.
    • Choose fats strategically: emphasize unsaturated fats (extra-virgin olive oil, nuts, seeds, avocado) and reduce saturated fat and trans fats (fatty/red processed meats, butter, pastries) to lower lipotoxicity and inflammation.
    • Limit alcohol (ideally avoid) and minimize ultra-processed foods, since alcohol and ultra-processed diets can worsen dysbiosis, gut permeability, oxidative stress, and liver inflammation.
    • Support metabolic health with protein and carbohydrate quality: include adequate protein from fish, poultry, tofu/tempeh, legumes, and low-fat dairy when tolerated; pair carbs with fiber/protein to improve insulin sensitivity.
    • If constipation or bloating is prominent, gradually titrate fiber and consider synbiotic/prebiotic options (e.g., yogurt/kefir with live cultures plus prebiotic foods) while monitoring tolerance to avoid symptom flare-ups.

  • Supplement considerations

    For MASH/NASH, supplements often target the gut–liver axis—especially the processes that drive dysbiosis, impaired intestinal barrier function, and heightened inflammatory signaling. Supporting the intestinal barrier may include approaches that encourage beneficial microbes (prebiotics, probiotics, and synbiotics), along with nutrients that help maintain epithelial integrity and reduce microbial translocation. Because gut-derived endotoxin signals such as LPS can activate innate immune pathways in the liver, interventions that help rebalance the microbiome and reduce inflammatory tone may be particularly relevant, especially in people who also report bloating, gas, or symptoms consistent with altered gut motility or fermentation.

    Another consideration is metabolic signaling and bile acid biology, both of which are heavily influenced by gut microbes and play central roles in insulin resistance and hepatic fat accumulation. Supplements that affect microbial metabolites and bile acid pathways (for example, via modulation of bile acid pools or enhancement of gut-derived short-chain fatty acid profiles) may help shift signaling toward improved glucose and lipid homeostasis. In practice, this often means choosing evidence-informed formulations aimed at microbial ecosystem balance and downstream metabolic effects rather than relying on a single “liver detox” product.

    Given that oxidative stress and inflammation contribute to steatohepatitis progression, antioxidants and anti-inflammatory support are commonly considered alongside microbiome-focused strategies. However, supplement selection should be coordinated with overall NAFLD/MASH management (diet quality, weight and insulin-sensitizing efforts, and clinician-directed monitoring of liver enzymes and fibrosis risk). Quality, dose, and tolerability matter—especially because some products can worsen GI symptoms or interact with medications—so it’s important to use standardized, well-characterized supplements and reassess response over time.

  • Retesting / monitoring note

    For people with MASH/NASH, retesting is typically considered to reassess disease activity, treatment response, and progression risk after an interval long enough for liver inflammation and fibrosis-related signals to change. Clinicians commonly use repeat evaluation of liver enzymes (e.g., ALT/AST), metabolic markers (such as fasting glucose and HbA1c), and non-invasive fibrosis assessments (e.g., FIB-4 or NAFLD fibrosis scoring). In the context of the gut–liver axis, retesting may also be timed alongside dietary or microbiome-targeted interventions to determine whether improvements in intestinal barrier function and microbial metabolite balance correlate with improved biochemical and clinical endpoints.

    Because gut dysbiosis and altered bile acid signaling can evolve over weeks to months, retesting after initiating or modifying a gut-supportive strategy (such as a Mediterranean-style or high-fiber diet, prebiotic/probiotic/synbiotic approaches, or bile-acid–modulating therapies when indicated) is often used to confirm trajectory rather than rely on a single measurement. Some protocols incorporate repeated stool- or blood-based biomarker panels related to inflammation and gut permeability (for example, markers reflecting LPS-driven immune activation or oxidative stress), alongside liver-focused tests. This helps determine whether changes in microbial metabolites (including short-chain fatty acids) and bile acid signaling are moving toward a less inflammatory, more protective pattern.

    Retesting frequency should also account for baseline fibrosis risk and how close the patient is to decision thresholds for escalating care. Patients with higher baseline risk (e.g., elevated non-invasive fibrosis scores, persistently raised aminotransferases, or metabolic syndrome that remains uncontrolled) may need earlier reassessment, whereas lower-risk patients may be monitored at longer intervals. Regardless of timing, the goal of retesting is to capture meaningful shifts in liver inflammation and cardiometabolic drivers of steatohepatitis, while monitoring for progression signals that may warrant further imaging, specialist evaluation, or changes in therapy.

The importance of gut microbiome testing

  • Why testing matters

    In MASH/NASH, gut microbiome imbalance can help explain the “gut–liver axis” that drives steatohepatitis progression. When the gut barrier becomes more permeable, microbial products such as lipopolysaccharide (LPS) and other metabolites may reach the liver via portal circulation, activating innate immune pathways (including Toll-like receptor signaling) and increasing inflammatory cytokines. Microbiome testing can provide insight into whether someone’s gut ecosystem shows dysbiosis patterns that are associated with higher inflammatory tone and impaired barrier-supportive signaling, helping personalize risk assessment beyond liver enzymes alone.

    Microbiome profiling may also be relevant because gut microbes influence metabolic pathways central to MASH/NASH, including insulin resistance and hepatic fat accumulation. Tests can help identify signatures linked to altered fermentation and short-chain fatty acid balance, changes in bile acid transformations, and shifts in signaling through receptors such as FXR and TGR5 that govern glucose and lipid homeostasis. Understanding these microbial and functional tendencies can support more tailored nutrition and gut-targeted interventions aimed at improving metabolic signaling, reducing inflammatory drive, and supporting healthier bile acid biology.

    Finally, gut microbiome testing can matter for monitoring and optimizing therapy. Because microbial communities respond to diet, fiber intake, prebiotics/probiotics/synbiotics, and other gut-directed strategies, serial testing can help determine whether the gut-liver inflammatory cycle is being corrected—such as improving barrier-associated microbial ecology, normalizing metabolite outputs, and potentially lowering pro-fibrotic risk signals. While testing doesn’t replace clinical evaluation, it can add actionable context for designing and tracking interventions that may slow MASH/NASH progression.

  • How InnerBuddies helps

    InnerBuddies can help provide personalized insight into the gut–liver axis that drives MASH/NASH by characterizing the gut microbiome patterns associated with dysbiosis and reduced barrier function. In people with steatohepatitis, a disrupted microbial ecosystem can increase intestinal permeability, making bacterial byproducts (such as lipopolysaccharide/LPS) and other inflammatory metabolites more likely to reach the liver via portal circulation. By identifying microbiome features that correlate with higher inflammatory tone and weaker gut-barrier support, InnerBuddies can add context to risk beyond liver enzymes and imaging alone.

    Because gut microbes also influence metabolism, InnerBuddies may help connect microbiome-derived functional tendencies with key MASH/NASH drivers like insulin resistance and hepatic fat accumulation. Microbial fermentation patterns and short-chain fatty acid (SCFA) balance—plus gut-shaped bile acid transformations that signal through receptors such as FXR and TGR5—can shift how the body regulates glucose, lipids, and inflammatory signaling. A microbiome-informed view can therefore support more tailored nutrition strategies aimed at improving metabolic signaling and reducing the signals that may contribute to ongoing liver injury.

    InnerBuddies testing can also be useful for monitoring and optimizing gut-targeted interventions over time. Since microbial communities respond to fiber intake, prebiotics, probiotics/synbiotics, and broader dietary changes, repeat testing can help determine whether the gut ecosystem is moving toward a less dysbiotic, more barrier-supportive profile. That can help you track whether interventions are helping calm gut-to-liver inflammatory communication—supporting a practical, individualized approach to slowing progression of MASH/NASH.

Medical Evidence

  • Scientific evidence level

    2 [weak/emerging but inconsistent]

  • Clinical relevance note

    At present, gut microbiome profiling is not validated for routine clinical decision-making in MASH/NASH. While many studies show statistically significant differences in stool microbiome patterns between people with NASH/steatohepatitis versus controls and/or with more advanced fibrosis, these differences are not reliably reproducible across cohorts and are not standardized enough for clinical use. Furthermore, correlation does not demonstrate that specific microbiome features are causal drivers rather than consequences of diet, obesity, insulin resistance, liver dysfunction, medication exposure, or unmeasured lifestyle factors.

    Clinically meaningful microbiome-targeted interventions remain investigational. Some dietary approaches, probiotics, or synbiotics may improve metabolic parameters and inflammatory/liver-related biomarkers in subsets of patients, and preclinical work suggests a gut–liver causal pathway is plausible. However, there is currently insufficient high-quality evidence demonstrating that manipulating the microbiome improves hard endpoints (biopsy-proven NASH resolution, meaningful fibrosis regression) or yields an approach with validated predictive performance and external validation for real-world clinical workflows. If future trials address (i) standardized microbiome measurement, (ii) histologic endpoints, (iii) adequate sample sizes, and (iv) prespecified, externally validated predictive signatures, the evidence could move from hypothesis-generating to clinically actionable.

Title Journal Year Link
Metformin targets the gut microbiome to improve metabolic disease Cell Metabolism 2015 View →
Gut microbiome dysbiosis is associated with progression of non-alcoholic fatty liver disease Gut 2013 View →
Microbiota-driven bile acid signaling and dysregulation of the hepatic immune microenvironment contributes to nonalcoholic steatohepatitis Cell Metabolism 2013 View →
Fecal microbiota transplantation reduces insulin resistance and hepatic steatosis in patients with type 2 diabetes Gastroenterology 2012 View →
Gut microbiota in human nonalcoholic fatty liver disease Nature Biotechnology 2011 View →

Frequently Asked Questions

    ¿Qué es MASH/NASH y en qué se diferencia de una simple esteatosis?
    MASH/NASH es una forma progresiva de enfermedad del hígado graso con inflamación y daño a los hepatocitos. A diferencia de la esteatosis simple, tiene un mayor riesgo de fibrosis, cirrosis y cáncer de hígado. El eje intestino–hígado está involucrado en la progresión mediante resistencia a la insulina, activación inmunitaria, estrés oxidativo y metabolitos microbianos.
    ¿Qué provoca la progresión hacia fibrosis o cirrosis en MASH/NASH?
    La progresión se debe a la resistencia a la insulin, obesidad, disfunción metabólica, inflamación hepática persistente, disbiosis del microbioma, endotoxinas y señales fibrogénicas.
    ¿Cómo se diagnostica MASH/NASH?
    El diagnóstico suele usar tests de función hepática (ALT/AST), imágenes, evaluación de factores de riesgo y, a veces, biopsia hepática. No hay una prueba única definitiva; consulta a un profesional.
    ¿Qué papel juega el microbioma en MASH/NASH?
    El microbioma puede alterar la permeabilidad intestinal, la producción de endotoxinas, el equilibrio de cagnutos de cadena corta, los ácidos biliares y señales metabólicas que influyen en la inflamación y la acumulación de grasa en el hígado.
    ¿Es útil la prueba del microbioma para MASH/NASH?
    Las pruebas pueden dar contexto, pero no son un estándar de atención. Pueden orientar estrategias dietéticas o dirigidas al microbioma; discútelo con un profesional.
    ¿Qué síntomas son típicamente observados?
    Fatiga, dolor o sensación de plenitud en la parte superior derecha del abdomen, cambios de peso, signos de resistencia a la insulina, hinchazón. En etapas avanzadas puede haber ictericia o acumulación de líquido.
    ¿Qué tan común es MASH/NASH y quién tiene mayor riesgo?
    NAFLD afecta alrededor del 25–30% de los adultos; NASH/MASH alrededor del 10–12%. El riesgo es mayor en diabetes tipo 2 y obesidad. Muchos presentan pocos síntomas en etapas tempranas.
    ¿Qué cambios de estilo de vida pueden ayudar?
    Pérdida de peso mediante dieta y ejercicio, dieta rica en fibra, limitar bebidas azucaradas y gestionar factores metabólicos; consulta a un médico para un plan personalizado.
    ¿Existen fármacos aprobados específicamente para NASH/MASH?
    No hay fármacos aprobados de forma universal específicamente para NASH/MASH. El tratamiento se centra en gestionar factores de riesgo; algunos fármacos están en investigación. Habla con un médico.
    ¿Cuál es la relación entre los ácidos biliares y MASH/NASH?
    Los microbios pueden cambiar el pool de ácidos biliares y la señalización a través de FXR y TGR5, afectando el metabolismo de la glucosa y de las grasas y la inflamación.
    ¿Qué significa un ALT/AST elevado en este contexto?
    ALT/AST elevados indican estrés o daño hepático, pero no confirman NASH por sí solos; se necesita evaluación médica adicional.
    ¿Cómo puede ayudar InnerBuddies con MASH/NASH?
    InnerBuddies ofrece ideas basadas en el microbioma sobre el eje intestino–hígado y puede ayudar a personalizar la alimentación y a seguir cambios a lo largo del tiempo; no sustituye el consejo médico.

    Hear from our satisfied customers!

    • "I would like to let you know how excited I am. We had been on the diet for about two months (my husband eats with us). We felt better with it, but how much better was really only noticed during the Christmas vacations when we had received a large Christmas package and didn't stick to the diet for a while. Well that did give motivation again, because what a difference in gastrointestinal symptoms but also energy in both of us!"

      - Manon, age 29 -

    • "Super help!!! I was already well on my way, but now I know for sure what I should and should not eat, drink. I have been struggling with stomach and intestines for so long, hope I can get rid of it now."

      - Petra, age 68 -

    • "I have read your comprehensive report and advice. Many thanks for that and very informative. Presented in this way, I can certainly move forward with it. Therefore no new questions for now. I will gladly take your suggestions to heart. And good luck with your important work."

      - Dirk, age 73 -